Abstract:
The objective of the study was to determine the efficacy and safety of tiludronate in the treatment of postmenopausal osteoporosis. Two placebo-controlled, randomized, double-masked, multicenter, cyclical, intermittent, dose-ranging studies including 1805 women with low vertebral bone mineral density and prevalent vertebral fractures and 488 women with low bone mineral density and no prevalent fracture were conducted. Patients were randomized to either tiludronate 50 mg/day, tiludronate 200 mg/day or placebo, given orally for the first 7 days of each month. A supplement of 500 mg elemental calcium was provided daily from day 8 to the end of the month. Both studies demonstrated no statistically or clinically relevant trends in the incidence of adverse effects accross the three treatment groups. However, tiludronate administered at these two doses in a cyclic intermittent regimen was not effective in reducing the incidence of vertebral fractures or increasing spinal bone mineral density. Thus, tiludronate, administered at these doses in a cyclic intermittent regimen, cannot be considered an appropriate treatment of postmenopausal osteoporosis, notwithstanding a high safety profile.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 6 July 2000 / Accepted: 25 September 2000
Rights and permissions
About this article
Cite this article
Reginster, J., Christiansen, C., Roux, C. et al. Intermittent Cyclic Tiludronate in the Treatment of Osteoporosis . Osteoporos Int 12, 169–177 (2001). https://doi.org/10.1007/s001980170126
Issue Date:
DOI: https://doi.org/10.1007/s001980170126